Osimertinib (OSI) vs Standard of Care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA

被引：0
|
作者：
Bischoff, H. G. [1 ]
Rueckert, A. [2 ]
Reinmuth, N. [3 ]
Grohe, C. [4 ]
Bohnet, S. [5 ]
zum Bueschenfelde, C. M. [6 ]
机构：
[1] Univ Heidelberg Hosp, Thoraxklin, Heidelberg, Germany
[2] Schwarzwald Baar Klinikum, Klin Innere Med Onkol Hamatol Immunol Infektiol &, Villingen Schwenningen, Germany
[3] Asklepios Fachkliniken Gauting, Onkol Klin Pneumol, Gauting, Germany
[4] Evangel Lungenklin Berlin, Klin Pneumol, Berlin, Germany
[5] UKSH Lubeck, Med Klin 3, Lubeck, Germany
[6] St Vincentius Kliniken, Karlsruhe Abt Innere Med 2, Karlsruhe, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
980
引用
收藏
页码：187 / 187
页数：1
相关论文
共 50 条
  • [1] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
    Ramalingam, S.
    Reungwetwattana, T.
    Chewaskulyong, B.
    Dechaphunkul, A.
    Lee, K. H.
    Imamura, F.
    Nogami, N.
    Ohe, Y.
    Cheng, Y.
    Cho, B. C.
    Cho, E. K.
    Vansteenkiste, J. F.
    Voon, P. J.
    Zhou, C.
    Gray, J.
    Hodge, R.
    Rukazenkov, Y.
    Soria, J-C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
    Planchard, D.
    Boyer, M.
    Lee, J-S.
    Dechaphunkul, A.
    Cheema, P.
    Takahashi, T.
    Todd, A.
    McKeown, A.
    Rukazenkov, Y.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S72 - S73
  • [3] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
    Planchard, D.
    Boyer, M.
    Lee, J-S.
    Dechaphunkul, A.
    Cheema, P.
    Takahashi, T.
    Todd, A.
    McKeown, A.
    Rukazenkov, Y.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2018, 29 : 169 - 169
  • [4] Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC
    Zhou, C.
    Cheng, Y.
    He, Y.
    Li, W.
    Zhang, H.
    Zhou, Q.
    Wang, B.
    Liu, C.
    Ramalingam, S.
    Walding, A.
    Saggese, M.
    Wang, J.
    Fan, M.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S507 - S508
  • [5] Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis
    Gray, J.
    Okamoto, I.
    Sriuranpong, V.
    Vansteenkiste, J.
    Imamura, F.
    Lee, J. S.
    Pang, Y.
    Cobo, M.
    Kasahara, K.
    Hodge, R.
    Lentrichia, B.
    Dearden, S.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1754 - S1755
  • [6] Osimertinib vs standard of care EGFR-TKI as first-line therapy in patients with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
    Grohe, C.
    Bischoff, H.
    Bohnet, S.
    zum Bueschenfelde, Meyer C.
    Reinmuth, N.
    Rueckert, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 269 - 269
  • [7] Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
    Ohe, Yuichiro
    Imamura, Fumio
    Nogami, Naoyuki
    Okamoto, Isamu
    Kurata, Takayasu
    Kato, Terufumi
    Sugawara, Shunichi
    Ramalingam, Suresh S.
    Uchida, Hirohiko
    Hodge, Rachel
    Vowler, Sarah L.
    Walding, Andrew
    Nakagawa, Kazuhiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (01) : 29 - 36
  • [8] CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study
    Vansteenkiste, J.
    Reungwetwattana, T.
    Nakagawa, K.
    Cho, B. C.
    Cobo Dols, M. A.
    Cho, E. K.
    Bertolini, A.
    Bohnet, S.
    Zhou, C.
    Lee, K. H.
    Nogami, N.
    Okamoto, I.
    Leighl, N.
    Hodge, R.
    McKeown, A.
    Brown, A. P.
    Rukazenkov, Y.
    Ramalingam, S.
    ANNALS OF ONCOLOGY, 2017, 28 : 189 - 189
  • [9] Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset
    Cho, Byoung Chul
    Chewaskulyong, Busayamas
    Lee, Ki Hyeong
    Dechaphunkul, Arunee
    Sriuranpong, Virote
    Imamura, Fumio
    Nogami, Naoyuki
    Kurata, Takayasu
    Okamoto, Isamu
    Zhou, Caicun
    Cheng, Ying
    Cho, Eun Kyung
    Voon, Pei Jye
    Lee, Jong-Seok
    Mann, Helen
    Saggese, Matilde
    Reungwetwattana, Thanyanan
    Ramalingam, Suresh S.
    Ohe, Yuichiro
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (01) : 99 - 106
  • [10] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset
    Cho, B. C.
    Chewaskulyong, B.
    Lee, K. H.
    Dechaphunkul, A.
    Sriuranpong, V.
    Imamura, F.
    Ohe, Y.
    Nogami, N.
    Kurata, T.
    Okamoto, I.
    Zhou, C.
    Cheng, Y.
    Cho, E. K.
    Jye, V. P.
    Lee, J-S.
    Mann, H.
    Saggese, M.
    Reungwetwattana, T.
    ANNALS OF ONCOLOGY, 2017, 28 : 190 - 190
12345